Wird geladen...
The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: who bears the cost?
OBJECTIVES: Poly(ADP-ribose) polymerase (PARP) inhibitors are expensive and their use is expanding. We aimed to evaluate cost sharing patterns between patients, payors, and financial assistance programs. METHODS: We identified ovarian cancer patients prescribed a PARP inhibitor from 5/2015–9/2019 us...
Gespeichert in:
| Veröffentlicht in: | Gynecol Oncol |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7902423/ https://ncbi.nlm.nih.gov/pubmed/33414026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.12.039 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|